脚手架跳跃方法用于设计和开发潜在的菌性AKT抑制剂
1Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. alireza110_p@yahoo.com.
Molecular biotechnology
|October 28, 2024
概括
研究人员使用脚手架跳跃设计了新的全性AKT抑制剂,用于癌症治疗. 三种化合物 (C6,C20,C16) 与三里宾相比,对AKT1具有更高的结合亲和力,需要进一步调查.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 计算生物学 计算生物学
背景情况:
- 向AKT对于癌症治疗至关重要,而全抑制剂提供了更大的特异性.
- 在许多癌症中,PI3K/Akt/mTOR通路是关键目标.
研究的目的:
- 设计新的全性AKT抑制剂,使用基于连接体/结构的管道和核心跳转.
- 为了确定具有更好的结合亲和力和特异性的强有力的AKT1抑制剂.
主要方法:
- 使用了脚手架跳跃方法,FDA批准的激酶抑制剂作为核心和triciribine作为模板.
- 采用了分子对接,ADME/T分析,分子动力学 (MD) 模拟和结合性自由能量计算.
- 对AKT1全位进行选的化合物.
主要成果:
- 设计了24种新的全性AKT抑制剂.
- 鉴定出三种化合物 (C6,C20,C16) 的结合亲和力显著高 (对接得分为-11到-13kcal/mol) 比triciribine (-8.6kcal/mol).
- MD模拟证实了在PH和激酶域中的关键AKT残留的向.
结论:
- 脚手架跳跃对于开发新型抗癌药物是有效的.
- 设计的化合物C6,C20和C16显示出作为AKT1抑制剂的显著潜力.
- 建议对这些有前途的候选物进行进一步的体外和体内实验验证.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K
Allosteric Regulation
57.7K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.7K
Structure-Activity Relationships and Drug Design
622
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
622
Assembly of Signaling Complexes
5.7K
Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
5.7K
Amplifying Signals via Enzymatic Cascade
8.3K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.3K


